ArticleInternational urology and nephrology2026
Evaluation of thulium laser endoscopic en bloc resection versus conventional trans-urethral en bloc resection of primary non-muscle invasive bladder cancer: a randomized controlled trial.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06818799 (Evaluation of Thulium Laser Endoscopic En-bloc Resection Versus Conventional Trans-urethral En-bloc Resection of Primary Non-muscle Invasive Bladder Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Thulium Laser Endoscopic En-bloc Resection Versus Conventional Trans-urethral En-bloc Resection of Primary Non-muscle Invasive Bladder Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare thulium laser endoscopic en bloc resection (TmLRBT) with bipolar transurethral en bloc resection (bERBT) for primary non-muscle-invasive bladder cancer.
methodsIn this multicenter, parallel-group randomized controlled trial, adults with primary urothelial tumors <3 cm and no clinical muscle invasion or metastasis were allocated 1:1 to TmLRBT or bERBT. The primary outcome was 12-month recurrence-free survival, assessed as recurrence-free status at 12 months and supported by time from index surgery to first documented bladder tumor recurrence or censoring within 12 months.
resultsOf the 69 patients assessed, 56 were randomized; 50 completed 12-month follow-up and were included in the complete case analysis. TmLRBT improved mean recurrence-free survival (11.6 ± 1.3 vs 10.0 ± 3.1 months; MD +1.60; 95% CI +0.23 to +2.97; p=0.023). Twelve-month recurrence was significantly lower after TmLRBT than bERBT (4/25 [16.0%] vs 12/25 [48.0%]; RR 0.33, 95% CI 0.12-0.89; p=0.032). TmLRBT prolonged surgery but reduced catheterization, hospitalization, irrigation, and obturator reflex, with no intraoperative bleeding, moderate postoperative bleeding, perforation, postoperative complications, or procedure-related deaths.
conclusionTmLRBT was associated with improved 12-month recurrence outcomes, longer mean recurrence-free survival, and favorable perioperative safety compared with bERBT.
trial registrationClinicalTrials.gov, NCT06818799, retrospectively registered February 10, 2025.
Indexed as
Identifiers
42771231What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.